8 Ways to Create Value in Cancer Care

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Benjamin J. Golas, MD

89Zr-DFO-daratumumab Has Potential Imaging Benefits in Non-FDG–Avid Multiple Myeloma

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Gina Mauro

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

89Zr-DFO-daratumumab shows activity in identifying and localizing multiple myeloma, even in FDG-non-avid cases, per new phase 2 data.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

Early Efficacy Seen With Gedatolisib-Based Therapies Prostate/Breast Cancers

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCPRC and mBC, respectively.

Tim Cortese

Exercise-Based Regimen Shows Efficacy Promise in CRC

Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCPRC and mBC, respectively.

Ariana Pelosci

High Tumor Volume Confers CAR T-Cell Therapy Toxicity Risk in LBCL

Nicholas J. Hornstein, MD, PhD, highlighted results from the phase 3 ATOMIC and CHALLENGE trials in CRC presented at the 2025 ASCO.

Related Content

Russ Conroy

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.

Benjamin J. Golas, MD

89Zr-DFO-daratumumab Has Potential Imaging Benefits in Non-FDG–Avid Multiple Myeloma

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Gina Mauro

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

89Zr-DFO-daratumumab shows activity in identifying and localizing multiple myeloma, even in FDG-non-avid cases, per new phase 2 data.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

Early Efficacy Seen With Gedatolisib-Based Therapies Prostate/Breast Cancers

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Tim Cortese

Exercise-Based Regimen Shows Efficacy Promise in CRC

Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCPRC and mBC, respectively.

Ariana Pelosci